Fort Sheridan Advisors LLC Has $976,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Fort Sheridan Advisors LLC increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 18.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,424 shares of the pharmaceutical company’s stock after buying an additional 386 shares during the period. Fort Sheridan Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $976,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Highline Wealth Partners LLC acquired a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $27,000. Dunhill Financial LLC increased its position in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares during the period. Brown Lisle Cummings Inc. acquired a new position in Vertex Pharmaceuticals in the fourth quarter valued at about $30,000. Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals during the third quarter worth about $33,000. Finally, Truvestments Capital LLC acquired a new stake in Vertex Pharmaceuticals during the third quarter worth about $35,000. 90.96% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Ourania Tatsis sold 310 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total value of $142,547.30. Following the transaction, the executive vice president now owns 64,021 shares in the company, valued at $29,438,776.43. The trade was a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Down 1.0 %

NASDAQ VRTX opened at $474.50 on Friday. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $121.85 billion, a PE ratio of -215.68, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The business’s 50-day moving average price is $438.74 and its two-hundred day moving average price is $460.99.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analyst Weigh In

VRTX has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $550.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 19th. UBS Group lifted their price target on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Scotiabank boosted their price target on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a “sector perform” rating in a report on Tuesday, February 11th. Finally, Citigroup initiated coverage on Vertex Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $575.00 price objective on the stock. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $506.70.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.